NAOV - NanoVibronix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

NanoVibronix, Inc.

525 Executive Boulevard
Elmsford, NY 10523
United States
914-233-3004
http://www.nanovibronix.com

SectorHealthcare
IndustryMedical Devices
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Mr. Brian M. MurphyCEO & Director281kN/A1957
Mr. Stephen R. Brown CPA, CPAConsultant175kN/A1956
Dr. William SternPresN/AN/A1942
Mr. James S. CardwellChief Financial OfficerN/AN/A1961
Mr. Amir RippelVP of MarketingN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.

Corporate Governance

NanoVibronix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.